title: In search for new antipsoriatic agents: NAD topical composition.
abstract: The aim of the study was to examine the effectiveness of the oxidized form of nicotinamide adenine dinucleotide (NAD(+)), adenosine precursor, in 37 patients suffering from psoriasis. As NAD(+) is known to be relatively unstable, the second goal was to establish the proper conditions for the satisfactory stability of topical NAD(+) composition. In each patient, two matching plaques were selected for the study. Topical treatment with 1 or 0.3% NAD(+) in Vaseline ointment administered twice daily was compared with overnight therapy with 0.1% anthralin applied for 12 h and placebo. The enzymatic method was applied to determine the stability of NAD(+) in Vaseline ointment. After a 4-week application, the reduction in erythema, infiltration and desquamation caused by 1 or 0.3% topical NAD(+) composition was similar to the reduction caused by 0.1% anthralin. It was demonstrated that NAD(+) underwent a considerable decomposition at room temperature, while it was sufficiently stable at 5 degrees C; thus, for a longer use the agent should be stored at fridge temperature. NAD(+) therapy combines good efficacy, cosmetic acceptability and convenient twice-daily application.
authors.affiliation: Department of Dermatology, Medical University, Lodz, Poland. wozniacka@bmp.net.pl
authors.forename: A
authors.initials: A
authors.lastname: Wozniacka
authors.forename: P
authors.initials: P
authors.lastname: Szajerski
authors.forename: J
authors.initials: J
authors.lastname: Adamus
authors.forename: J
authors.initials: J
authors.lastname: Gebicki
authors.forename: A
authors.initials: A
authors.lastname: Sysa-Jedrzejowska
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000875:Anthralin / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004355:Drug Stability; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009243:NAD / Q000008:administration & dosage / Q000627:therapeutic use*; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D003879:Dermatologic Agents; D009824:Ointments; D009243:NAD; D000875:Anthralin